Why TAL Education Group (TAL) Went Down On Friday?
We recently published a list of . In this article, we are going to take a look at where TAL Education Group (NYSE:TAL) stands against other firms that suffer amid optimistic market environment.
Wall Street's main indices recovered losses on Friday, as investors repositioned portfolios while digesting the ongoing trade tensions between the world's two largest economies.
After a battering this week, the Nasdaq finished the day up 2.06 percent; the S&P 500 rose 1.81 percent; and the Dow Jones grew 1.56 percent.
Ten companies, on the other hand, defied a wider market optimism, recording modest losses during the day. In this article, we have listed Friday's worst performers and detailed the reasons behind their declines.
To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million trading volume.
A teacher providing personalized instruction to a student in a small class environment.
TAL Education declined by 3.61 percent on Friday to end at $9.60 each as investors resumed disposing of shares in the company amid the ongoing trade war and ahead of its earnings results for the fourth quarter and fiscal year of 2025.
According to TAL, it would release its financial performance for the fourth quarter and fiscal year ended February 28, 2025, before the market opens on April 24, 2025.
Earlier this month, TAL officially entered the oversold territory, hitting a relative strength index reading of 29.1.
TAL is investing heavily in Artificial Intelligence in a bid to bolster its modern learning products and services.
Just recently, it launched what it called the 'Genius Tutor,' an AI-powered system that transforms learning into an interactive and engaging experience.
The GeniusTutor was built on the Microsoft Azure OpenAI GPT-4o model, which provides real-time guidance and feedback.
Overall, TAL ranks 4th on our list of firms that suffer amid optimistic market environment. While we acknowledge the potential of TAL as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than TAL but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Is AGNC Investment Worth Buying Today? The Answer May Surprise You.
AGNC Investment is a mortgage REIT. The value of the company is basically the value of its mortgage securities portfolio. The value of AGNC Investment's portfolio has been shrinking for years. 10 stocks we like better than AGNC Investment Corp. › AGNC Investment (NASDAQ: AGNC) has a gigantic 15%+ dividend yield. That lofty yield sounds very enticing, but sometimes things that sound too good to be true are, in fact, too good to be true. Here's why investors need to take a very nuanced view of AGNC Investment and how the company may actually be helping you decide when to buy the stock. Property-owning real estate investment trusts (REITs) buy physical properties and lease them out to tenants. That's what you would do if you owned a rental property, so it's probably fairly easy to wrap your head around the business model. Mortgage REITs like AGNC Investment buy mortgages that have been pooled together into bond-like securities. That's a lot more complex and you probably couldn't mimic that in your own investment life. Everything from interest rates to mortgage repayment rates can impact the value of mortgage securities. So even tracking what is going on within AGNC Investment's portfolio, or within any mortgage REIT, would be hard for most investors. Adding to the complexity is that mortgage securities trade all day long, so the portfolio's characteristics can change fairly quickly. This is not an investment for conservative income investors. That fact is highlighted by the steady downtrend in the dividend over the last decade or so, as the chart below highlights. Not surprisingly, the price of the stock has trailed the falling dividend. That said, AGNC Investment's value is basically the value of its portfolio of mortgage securities. In that way it is kind of similar to a mutual fund. And, like a mutual fund, AGNC Investment reports the value of its portfolio on a per-share basis. It calls this number tangible net book value per share. It only reports that number quarterly, but it is an important figure to monitor. At the end of the first quarter of 2025 AGNC Investment's tangible net book value per share was $8.25. At the end of the first quarter of 2022 it was $13.12. Tangible net book value per share can rise and fall fairly dramatically at times, depending on the market environment. Over the past year, for example, this metric has risen and fallen by 5% between quarters multiple times. It is, at best, a rough gauge for investors to monitor between quarters. But the really interesting thing here is that AGNC Investment's stock price often trades above tangible net book value per share. Sometimes dramatically above the number -- the 52-week high is $10.85 even though the reported tangible net book value per share never rose above $8.84 in any of the last four quarters. This is great news for shareholders, since AGNC Investment frequently sells new shares to the public to raise additional capital. Every penny above tangible net book value that a new buyer pays is tantamount to giving current shareholders free money. Management even explains this fact when it discusses stock sales, saying things like the company "opportunistically" raised money "at a considerable premium to tangible net book value" and that this brings "meaningful book value accretion to our common stockholders." The takeaway here is pretty clear. Nobody should pay more than tangible net book value per share for AGNC Investment unless they believe that number is going to be headed sharply higher. But sometimes AGNC Investment's share price dips below that figure, with the 52-week low coming in at $7.85. The company would likely not be raising capital at that price, given that it would destroy value for current shareholders. However, if you buy the stock on the open market below book value you are increasing the chances that you are getting a good deal on the stock. The problem with this discussion is that it doesn't address the dividend or the dividend yield. That's because the company's focus isn't income, it is total return. The dividend is a part of total return, but total return assumes the dividend is reinvested. But a key part of total return is also the price you pay for the investment. If you bought at the 52-week high price of $10.85 per share, your total return would be terrible here even with the huge dividend yield. However, if you kept a close eye on tangible book value per share and only bought when the stock price was at or below the last reported figure, your total return would likely still be positive, helped along by that lofty yield. Before you buy stock in AGNC Investment Corp., consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and AGNC Investment Corp. wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Is AGNC Investment Worth Buying Today? The Answer May Surprise You. was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
43 minutes ago
- Yahoo
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
Hims & Hers stock is on the upswing after the company secured a weight-loss drug partnership. Hims & Hers is acquiring its way into Europe and wants to build more personalized drugs for its telehealth customers. Shares have soared, but still have a ton of potential for patient long-term shareholders. 10 stocks we like better than Hims & Hers Health › Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (NYSE: HIMS) may finally be succeeding in cracking the code. The online telehealth platform focuses on circumventing the insurance market; its business of selling affordable medications directly to individuals is growing like a weed, and expects to generate $6.5 billion in revenue by 2030. It has had a tumultuous start to 2025, as Hims & Hers waged a battle to sell new weight loss medications on its online marketplace. Now, with momentum back on its side, the stock is up 118% year to date and 446% in the last five years. Let's take a deeper look at this company, and see whether you might want to buy Hims & Hers stock for your portfolio now. Hims & Hers' model is simple. It has two separate web platforms -- Hims for men and Hers for women -- that sell medications and deliver to customers' front doors. It began with sexual health, but has moved into dermatology, hair loss, mental health, and now weight loss medications. A key to its success has been avoiding the insurance market with products that don't break the bank. Customers loathe dealing with health insurers in the United States, and sometimes would rather not use insurance at all. Plus, some of these products aren't covered by insurance. This strategy has helped the company close in on over $2 billion in projected revenue in 2025. To keep up this impressive growth, Hims & Hers wants to offer weight loss medications, which have been a blockbuster set of drugs for the pharmaceutical market. For a while the popularity of these drugs, such as Novo Nordisk's Wegovy, left them in short supply; that allowed third parties such as Hims & Hers to produce them as a compounding pharmacy and sell them at much cheaper prices. This ended up generating $200 million of Hims & Hers' $1.4 billion in 2024 revenue. But with the shortage of Wegovy over and the compounding pharmacy exception ended, the company's weight-loss business was at a major turning point. Luckily, at the end of April Hims & Hers announced a partnership with Novo Nordisk that seems to resolve this issue: It gives Hims & Hers the ability to sell Wegovy directly on its platform. Hims & Hers is not an exclusive supplier of the drug -- or any drugs on its marketplaces, to be fair -- but it hopes to use its subscription business model, marketing expertise, and simplified user proposition to drive sales for Novo Nordisk in the huge obesity-care market. Besides weight loss drugs, Hims & Hers has more ambitions to reach its goal of $6.5 billion in revenue by 2030. Just recently, the company announced its intent to acquire European competitor Zava so it could expand its telehealth service to Europe. The acquisition will add a platform with 1.3 million active customers in the U.K., Germany, France, and Ireland. It makes sense that Hims & Hers can supercharge growth for the platform with its plethora of medications offered to customers, keen marketing skills, and subscription-based selling model. Over the long run, Hims & Hers aims to make healthcare for its customers more personalized. This includes unique drug combinations, its own outsourcing facility, and at-home testing capabilities. Details remain sparse, but the vision is clear: disrupting more and more of the trillions of dollars spent on healthcare by building a business that people actually enjoy interacting with. This is why 2.4 million active customers use Hims & Hers today. A revenue goal of $6.5 billion seems well within reach by 2030. Hims & Hers is only at 2.4 million active customers, and there are tens of millions of people in the United States alone who could start using or switch to one of its telehealth platforms. Add on the Zava acquisition in Europe, and the runway for growth gets even larger. The company has an impressive gross profit margin of 77%, which should lead to high levels of profitability at scale. On $6.5 billion in future revenue, it could very well post a net profit margin of over 20%, and achieve $1.5 billion in bottom-line profits and free cash flow. A 20% profit margin is easily achievable because of its high gross margins and the fact it currently spends 40% of revenue on marketing today, a figure that has come down over time and should come down even more as Hims & Hers keeps scaling. However, Hims & Hers has played fast and loose with laws and regulations in the past. It sold weight loss drugs when the legality of doing so was unclear, and although that dispute seems to have been resolved, management could easily start playing with fire again and burn its reputation as a trusted provider of medications. Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today, Hims & Hers has a market cap of $12.3 billion. You might think it's overvalued because of the stock's recent run-up in price, but the numbers show that patient investors could be rewarded by holding for the long term. A $12.3 billion market cap is only around 8 times my 2030 earnings estimate of $1.5 billion, which would be a dirt cheap price-to-earnings (P/E) ratio for a fast-growing company compared to the current market cap. Most likely, the stock will be valued at a higher multiple than 8, meaning that the stock will be higher in five years. It doesn't come without risks, but if you're a growth investor, you might love Hims & Hers stock for its long-term potential. Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Down 21%, Should You Buy the Dip on Apple Stock? The Answer Might Surprise You.
It's the combination of products and services that has made Apple one of the best businesses on Earth. Ongoing uncertainty surrounding the tariff situation adds to investor concerns. At the current valuation, Apple stock provides zero margin of safety. 10 stocks we like better than Apple › Apple (NASDAQ: AAPL) shares are down 18% in 2025 (as of June 6). This makes Apple the worst-performing "Magnificent Seven" constituent this year, besides Tesla. Investors are probably concerned about tariff uncertainty and the company's slow progress with artificial intelligence (AI). The stock is currently 21% below its peak. So, it has some work to do to get back to its former glory. Legendary investor Warren Buffett and his conglomerate, Berkshire Hathaway, have sold a sizable chunk of their shares in the past several quarters. However, should you go against the Oracle of Omaha's moves and buy the dip on Apple stock? I think the answer might surprise you. I mention Buffett because many individual investors like to follow his buy and sell decisions. Clearly, when Berkshire first bought Apple in early 2016, they must've thought the tech giant was a high-quality enterprise. It's not hard to see why. Apple's brand is arguably the most recognizable in the world. This position wasn't created overnight. It took years and years of introducing truly exceptional products and services, that were well designed and incredibly easy to use, on a global scale. Apple is an icon, to say the least. That brand has helped drive Apple's pricing power. And this supports the company's unrivaled financial position. Apple remains an unbelievably profitable business. It brought in $24.8 billion in net income in the latest fiscal quarter (Q2 2025 ended March 29). Apple's products and services are impressive on their own. However, it's the combination of both of these aspects that creates the powerful ecosystem. Consumers are essentially locked in, which creates high barriers for them to switch to competing products. This favorable setup places Apple in an enviable position from a competitive perspective. Despite Apple's market cap of nearly $3.1 trillion, which might make some investors believe it's immune to external challenges, this business is dealing with some notable issues recently. There are three that immediately come to mind. The first problem is that Apple's growth engine seems to be decaying. Net sales were up less than 7% between fiscal 2021 and fiscal 2024. And they're up just over 4% through the first six months of fiscal 2025. According to management, there are likely over 2.4 billion active Apple devices across the globe. That number continues to rise with every passing quarter, but you get an idea of how ubiquitous these products are. Plus, the maturity of the iPhone, now almost two decades into its lifecycle, might lead to limited opportunities to further penetrate markets. Critics can also call out Apple's slow entrance into the AI race. For example, we won't see an AI update to Siri until next year, a launch that was delayed. At the same time, it seems like other companies are moving rapidly to win the AI race. Lastly, Apple has been and could continue to be drastically impacted by the tariff situation. China, which has gotten the most attention from President Donald Trump during the ongoing trade tensions, has been a manufacturing powerhouse for Apple. The business is being forced to shift its supply chain around to minimize the impact. Apple CEO Tim Cook said that the situation makes it challenging to forecast near-term results. Even though this stock trades 21% off its peak, investors aren't really getting a bargain deal here. The price-to-earnings ratio is 32 right now. That's not cheap for a company whose earnings per share are only expected to grow at a compound annual rate of 8.8% between fiscal 2024 and fiscal 2027. In my view, there's zero margin of safety. If you're an investor who wants to generate market-beating returns over the next five years, I don't think you should buy Apple today. Before you buy stock in Apple, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Apple wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Neil Patel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple, Berkshire Hathaway, and Tesla. The Motley Fool has a disclosure policy. Down 21%, Should You Buy the Dip on Apple Stock? The Answer Might Surprise You. was originally published by The Motley Fool
